Get started
Author

Mona Shafey

Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values
2022 · Christina S. Thornton, Kevin Huntley, et al. · Antimicrobial Resistance and Infection Control · 46
PDF
Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation
2013 · James A. Russell, Shahbal B. Kangarloo, et al. · Transplantation and Cellular Therapy · 39
PDF
Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing
2011 · S. Bill Kangarloo, Farrukh Naveed, et al. · Transplantation and Cellular Therapy · 38
PDF
Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment
2010 · M Shafey, S M Lupichuk, et al. · Bone Marrow Transplantation · 35
Factor XIII Val34Leu variant and the risk of myocardial infarction
2007 · Mona Shafey, Josdalyne Anderson, et al. · Thrombosis and Haemostasis · 35
Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities
2012 · Andrew Daly, Mary L. Savoie, et al. · Transplantation and Cellular Therapy · 26
PDF
Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation
2021 · Megan Kinzel, Michelle Dowhan, et al. · Transplantation and Cellular Therapy · 24
PDF
Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder
2022 · Megan Kinzel, Amit Kalra, et al. · Transplantation and Cellular Therapy · 17
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients
2019 · Sheilagh Sanders, Neil Chua, et al. · Transplantation and Cellular Therapy · 16
PDF
Long‐term follow‐up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
2023 · Robert Puckrin, Neil Chua, et al. · British Journal of Haematology · 12
Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma
2011 · Mona Shafey, Qiuli Duan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 11
The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review
2023 · Robert Puckrin, Mona Shafey, et al. · Frontiers in Oncology · 10
PDF
Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
2022 · Lina Nunez, Tasnima Abedin, et al. · Blood Advances · 10
Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis
2022 · Robert Puckrin, Douglas A. Stewart, et al. · Transplantation and Cellular Therapy · 9
Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada
2025 · Isabelle Fleury, David Macdonald, et al. · Current Oncology · 8
Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis
2023 · Robert Puckrin, Carolyn Owen, et al. · Bone Marrow Transplantation · 8
Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation
2021 · Rutvij A. Khanolkar, Rehan M. Faridi, et al. · Cytotherapy · 8
High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma
2013 · Archana Vijay, Qiuli Duan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 8
Canadian Cancer Trials Group (cctg) Ly.17: a Randomized Phase Ii Study Evaluating Novel Salvage Therapy Pre‐autologous Stem Cell Transplant (asct) in Relapsed/refractory Diffuse Large B Cell Lymphoma (rr‐dlbcl) ‐ Outcome of Ibrutinib + R‐gdp
2017 · J. Kuruvilla, M. Crump, et al. · Hematological Oncology · 7
PDF
Anti‐myeloma potential of ruxolitinib in co‐existing JAK2V617F‐positive smouldering myeloma and polycythaemia vera
2020 · Holly Lee, Sylvia McCulloch, et al. · British Journal of Haematology · 6
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 5
Canadian cancer trials group LY .17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐ DICEP ) versus R‐ GDP
2024 · Douglas A. Stewart, John Kuruvilla, et al. · British Journal of Haematology · 5
Highlights from ASCO 2020: Updates on the Treatment of Chronic Lymphocytic Leukemia
2020 · S. Dolan, A. Christofides, et al. · Current Oncology · 5
PDF
Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)
2023 · Neil Berinstein, Kim Roos, et al. · Blood · 4
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors
2026 · Franz J. Zemp, Zackariah Breckenridge, et al. · Nature Cancer · 3
Works count: 74
Citation count: 437
H-index: 11
I10-index: 13
Year
Topic
Type